NZ592977A - IgE CH3 PEPTIDE VACCINE - Google Patents

IgE CH3 PEPTIDE VACCINE

Info

Publication number
NZ592977A
NZ592977A NZ592977A NZ59297709A NZ592977A NZ 592977 A NZ592977 A NZ 592977A NZ 592977 A NZ592977 A NZ 592977A NZ 59297709 A NZ59297709 A NZ 59297709A NZ 592977 A NZ592977 A NZ 592977A
Authority
NZ
New Zealand
Prior art keywords
ige
peptide vaccine
immunogenic carrier
ige peptide
antigenic
Prior art date
Application number
NZ592977A
Other languages
English (en)
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of NZ592977A publication Critical patent/NZ592977A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ592977A 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE NZ592977A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09
PCT/IB2009/055508 WO2010067286A2 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE

Publications (1)

Publication Number Publication Date
NZ592977A true NZ592977A (en) 2013-01-25

Family

ID=42035836

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ604186A NZ604186A (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine
NZ592977A NZ592977A (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ604186A NZ604186A (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine

Country Status (22)

Country Link
US (3) US8298547B2 (ja)
EP (2) EP2865389A1 (ja)
JP (4) JP5209800B2 (ja)
KR (3) KR101634058B1 (ja)
CN (1) CN102245198B (ja)
AR (1) AR074505A1 (ja)
AU (1) AU2009325950B2 (ja)
BR (1) BRPI0922561A2 (ja)
CA (1) CA2744754A1 (ja)
CO (1) CO6561830A2 (ja)
DK (1) DK2376108T3 (ja)
ES (1) ES2622562T3 (ja)
HK (1) HK1163511A1 (ja)
IL (1) IL213029A0 (ja)
MX (2) MX337723B (ja)
NZ (2) NZ604186A (ja)
PE (2) PE20142330A1 (ja)
RU (1) RU2495049C2 (ja)
SG (2) SG10201400388QA (ja)
TW (1) TWI387463B (ja)
WO (1) WO2010067286A2 (ja)
ZA (1) ZA201104072B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039978A (ko) * 2005-08-11 2008-05-07 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련펩티드
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
CA2954278A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
CA2954687A1 (en) 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
KR102230325B1 (ko) * 2015-09-30 2021-03-19 시오노기 앤드 컴파니, 리미티드 면역 부활 활성을 갖는 핵산 유도체
KR101876620B1 (ko) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
MY186779A (en) * 2017-03-29 2021-08-19 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
US20230364232A1 (en) 2020-09-17 2023-11-16 Neovacs IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
WO2023192203A2 (en) * 2022-03-28 2023-10-05 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69718150T3 (de) 1996-03-01 2009-03-05 Novartis Ag Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6231864B1 (en) 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
CN1296416A (zh) 1998-04-09 2001-05-23 史密丝克莱恩比彻姆生物有限公司 佐剂组合物
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU6022399A (en) 1998-09-03 2000-03-27 Chiron Corporation Angiogenically effective unit dose of fgf-2 and method of use
DE59806475D1 (de) 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase-inhibitoren
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000026385A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
EP1135162B1 (en) 1998-11-30 2008-10-29 Cytos Biotechnology AG Ordered molecular presentation of allergens, method of preparation and use
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
AU3281100A (en) * 1999-02-25 2000-09-14 Peptide Therapeutics Limited Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
EP1082346A1 (en) * 1999-03-30 2001-03-14 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
HU229255B1 (en) 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
ES2265980T5 (es) 1999-09-27 2010-12-28 Coley Pharmaceutical Group, Inc. Metodos relacionados con interferón inducido por ácidos nucleicos inmunoestimuladores.
US7270821B2 (en) 2000-04-07 2007-09-18 University Of Leeds Innovations Limited Hepatitis B core antigen fusion proteins
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
DK1294893T3 (da) 2000-06-22 2006-07-03 Ucb Pharma Ltd Modifikation af hepatitis B-kerneantigen
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP1967205B1 (en) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
WO2004007538A2 (en) 2002-07-17 2004-01-22 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
KR100991679B1 (ko) 2002-12-10 2010-11-04 셀덱스 테라퓨틱스 리미티드 안정화 면역원성 ＨＢｃ 키메라 입자
ZA200507562B (en) * 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
SG149892A1 (en) 2004-02-02 2009-02-27 Tanox Inc Identification of novel ige epitopes
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ES2526879T3 (es) 2006-02-15 2015-01-16 Adiutide Pharmaceuticals Gmbh Composiciones y procedimientos para formulaciones de oligonucleótidos
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
BRPI0809677A2 (pt) 2007-04-02 2014-10-07 Pfizer Anticorpos anti-ige
WO2008145400A2 (en) * 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
ES2893464T3 (es) 2016-06-23 2022-02-09 Ripples Ltd Procedimiento y aparato para imprimir en una bebida

Also Published As

Publication number Publication date
KR20150056881A (ko) 2015-05-27
RU2011121043A (ru) 2013-01-20
TW201036632A (en) 2010-10-16
US8475801B2 (en) 2013-07-02
BRPI0922561A2 (pt) 2020-08-11
CN102245198B (zh) 2016-08-17
RU2495049C2 (ru) 2013-10-10
JP2012255006A (ja) 2012-12-27
JP5367137B2 (ja) 2013-12-11
KR20130032390A (ko) 2013-04-01
ES2622562T3 (es) 2017-07-06
WO2010067286A2 (en) 2010-06-17
JP5209800B2 (ja) 2013-06-12
JP2016164156A (ja) 2016-09-08
SG186611A1 (en) 2013-01-30
IL213029A0 (en) 2011-07-31
US20100158933A1 (en) 2010-06-24
CN102245198A (zh) 2011-11-16
JP2012511322A (ja) 2012-05-24
JP5964280B2 (ja) 2016-08-03
SG10201400388QA (en) 2014-05-29
KR101644221B1 (ko) 2016-07-29
CA2744754A1 (en) 2010-06-17
DK2376108T3 (en) 2017-04-24
PE20142330A1 (es) 2015-01-14
TWI387463B (zh) 2013-03-01
US8298547B2 (en) 2012-10-30
US9216229B2 (en) 2015-12-22
KR101413844B1 (ko) 2014-06-30
CO6561830A2 (es) 2012-11-15
MX2011006077A (es) 2011-09-01
AU2009325950A1 (en) 2010-06-17
ZA201104072B (en) 2012-02-29
KR101634058B1 (ko) 2016-06-27
MX337723B (es) 2016-03-15
US20140017239A1 (en) 2014-01-16
PE20110891A1 (es) 2011-12-23
EP2865389A1 (en) 2015-04-29
WO2010067286A3 (en) 2010-08-05
EP2376108B1 (en) 2017-02-22
AR074505A1 (es) 2011-01-19
NZ604186A (en) 2014-07-25
EP2376108A2 (en) 2011-10-19
HK1163511A1 (zh) 2012-09-14
US20120294848A1 (en) 2012-11-22
AU2009325950B2 (en) 2013-03-07
JP2014012009A (ja) 2014-01-23
KR20110094134A (ko) 2011-08-19

Similar Documents

Publication Publication Date Title
NZ592977A (en) IgE CH3 PEPTIDE VACCINE
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB9923176D0 (en) Novel composition
GEP20227386B (en) Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
CO6150189A2 (es) Vacunas para malaria
ME01199B (me) Nove kompozicije adjuvanta
CO6321162A2 (es) Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
JP2009501901A5 (ja)
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
EP2444103A4 (en) VACCINE AGAINST NUTRITIONAL CANCER
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
WO2010086743A3 (en) Codon-optimised hepatitis b virus core antigen
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
MX2010006984A (es) Vacunas contra la malaria.
PT2222335T (pt) Composições imunogénicas e de vacina do vírus da língua azul, métodos de utilização e métodos de produção das mesmas
CO6341568A2 (es) Composicion inmunologica
TW200612983A (en) Vaccine
WO2010111586A3 (en) Mucosal immunization

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 DEC 2016 BY THOMSON REUTERS

Effective date: 20130920

LAPS Patent lapsed